The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and α2-antiplasmin dependent

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Carbon monoxide derived from a carbon monoxide-releasing molecule [tricarbonyldichlororuthenium (II) dimer; CORM-2] has been recently demonstrated to diminish tissue-type plasminogen activator (tPA)-mediated fibrinolysis of plasma thrombi via enhancement of α2-antiplasmin-plasmin interactions. The goal of this study was to confirm this mechanism by comparing tPA-mediated fibrinolysis with fibrin-independent, α2- antiplasmin-resistant streptokinase-mediated fibrinolysis in CORM-2 exposed plasma. Normal plasma was exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor and fibrinolysis initiated with 100 U/ml tPA or 50 U/ml streptokinase. Thrombus growth/disintegration kinetics were monitored with thrombelastography until clot lysis time occurred. Unlike tPA-lysed clots, streptokinase-exposed thrombi demonstrated no significant CORM-2-mediated prolongation of clot growth time or clot lysis time. In contrast, streptokinase-mediated lysis did not significantly change the CORM-2-mediated percentage increase in the maximum rate of clot growth or maximum rate of clot lysis compared with tPA-exposed thrombi. CORM-2 likely attenuates fibrinolysis by a fibrin-dependent/α2-antiplasmin-dependent mechanism. Additional molecular investigation (e.g., mass spectroscopy) is planned to further elucidate how CORM-2 modifies fibrinogen/fibrin.

Original languageEnglish (US)
Pages (from-to)584-587
Number of pages4
JournalBlood Coagulation and Fibrinolysis
Volume21
Issue number6
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Antifibrinolytic Agents
Carbon Monoxide
Fibrin
Fibrinolysis
Streptokinase
Plasminogen Activators
Thrombosis
Fibrin Clot Lysis Time
Growth
Thrombelastography
tricarbonyldichlororuthenium (II) dimer
Fibrinolysin
Urokinase-Type Plasminogen Activator
Thromboplastin
Tissue Plasminogen Activator
Fibrinogen
Mass Spectrometry

Keywords

  • carbon monoxide-releasing molecule
  • fibrinolysis
  • streptokinase
  • thrombelastography
  • tissue-type plasminogen activator

ASJC Scopus subject areas

  • Hematology

Cite this

@article{3a6a4d5b53b043f2bfb7fe748018c597,
title = "The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and α2-antiplasmin dependent",
abstract = "Carbon monoxide derived from a carbon monoxide-releasing molecule [tricarbonyldichlororuthenium (II) dimer; CORM-2] has been recently demonstrated to diminish tissue-type plasminogen activator (tPA)-mediated fibrinolysis of plasma thrombi via enhancement of α2-antiplasmin-plasmin interactions. The goal of this study was to confirm this mechanism by comparing tPA-mediated fibrinolysis with fibrin-independent, α2- antiplasmin-resistant streptokinase-mediated fibrinolysis in CORM-2 exposed plasma. Normal plasma was exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor and fibrinolysis initiated with 100 U/ml tPA or 50 U/ml streptokinase. Thrombus growth/disintegration kinetics were monitored with thrombelastography until clot lysis time occurred. Unlike tPA-lysed clots, streptokinase-exposed thrombi demonstrated no significant CORM-2-mediated prolongation of clot growth time or clot lysis time. In contrast, streptokinase-mediated lysis did not significantly change the CORM-2-mediated percentage increase in the maximum rate of clot growth or maximum rate of clot lysis compared with tPA-exposed thrombi. CORM-2 likely attenuates fibrinolysis by a fibrin-dependent/α2-antiplasmin-dependent mechanism. Additional molecular investigation (e.g., mass spectroscopy) is planned to further elucidate how CORM-2 modifies fibrinogen/fibrin.",
keywords = "carbon monoxide-releasing molecule, fibrinolysis, streptokinase, thrombelastography, tissue-type plasminogen activator",
author = "Nielsen, {Vance G}",
year = "2010",
month = "9",
doi = "10.1097/MBC.0b013e32833cea13",
language = "English (US)",
volume = "21",
pages = "584--587",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and α2-antiplasmin dependent

AU - Nielsen, Vance G

PY - 2010/9

Y1 - 2010/9

N2 - Carbon monoxide derived from a carbon monoxide-releasing molecule [tricarbonyldichlororuthenium (II) dimer; CORM-2] has been recently demonstrated to diminish tissue-type plasminogen activator (tPA)-mediated fibrinolysis of plasma thrombi via enhancement of α2-antiplasmin-plasmin interactions. The goal of this study was to confirm this mechanism by comparing tPA-mediated fibrinolysis with fibrin-independent, α2- antiplasmin-resistant streptokinase-mediated fibrinolysis in CORM-2 exposed plasma. Normal plasma was exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor and fibrinolysis initiated with 100 U/ml tPA or 50 U/ml streptokinase. Thrombus growth/disintegration kinetics were monitored with thrombelastography until clot lysis time occurred. Unlike tPA-lysed clots, streptokinase-exposed thrombi demonstrated no significant CORM-2-mediated prolongation of clot growth time or clot lysis time. In contrast, streptokinase-mediated lysis did not significantly change the CORM-2-mediated percentage increase in the maximum rate of clot growth or maximum rate of clot lysis compared with tPA-exposed thrombi. CORM-2 likely attenuates fibrinolysis by a fibrin-dependent/α2-antiplasmin-dependent mechanism. Additional molecular investigation (e.g., mass spectroscopy) is planned to further elucidate how CORM-2 modifies fibrinogen/fibrin.

AB - Carbon monoxide derived from a carbon monoxide-releasing molecule [tricarbonyldichlororuthenium (II) dimer; CORM-2] has been recently demonstrated to diminish tissue-type plasminogen activator (tPA)-mediated fibrinolysis of plasma thrombi via enhancement of α2-antiplasmin-plasmin interactions. The goal of this study was to confirm this mechanism by comparing tPA-mediated fibrinolysis with fibrin-independent, α2- antiplasmin-resistant streptokinase-mediated fibrinolysis in CORM-2 exposed plasma. Normal plasma was exposed to 0 or 100 μmol/l CORM-2, with coagulation activated with tissue factor and fibrinolysis initiated with 100 U/ml tPA or 50 U/ml streptokinase. Thrombus growth/disintegration kinetics were monitored with thrombelastography until clot lysis time occurred. Unlike tPA-lysed clots, streptokinase-exposed thrombi demonstrated no significant CORM-2-mediated prolongation of clot growth time or clot lysis time. In contrast, streptokinase-mediated lysis did not significantly change the CORM-2-mediated percentage increase in the maximum rate of clot growth or maximum rate of clot lysis compared with tPA-exposed thrombi. CORM-2 likely attenuates fibrinolysis by a fibrin-dependent/α2-antiplasmin-dependent mechanism. Additional molecular investigation (e.g., mass spectroscopy) is planned to further elucidate how CORM-2 modifies fibrinogen/fibrin.

KW - carbon monoxide-releasing molecule

KW - fibrinolysis

KW - streptokinase

KW - thrombelastography

KW - tissue-type plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=77955918004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955918004&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32833cea13

DO - 10.1097/MBC.0b013e32833cea13

M3 - Article

VL - 21

SP - 584

EP - 587

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 6

ER -